Abstract
Since the discovery of dendritic cells (DC) as potent stimulators of immune responses by Zanvil Cohn and Ralph Steinman in the 1970s, the idea that DC could be used as adjuvants for activation of antitumor immunity steadily gained traction, culminating in the first published clinical trial of DC vaccination (for treatment of B cell lymphoma) (1).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
